Fluorescent Probes for Live Cell Imaging

Chen, Zhijie; Lukinavičius, Gražvydas

doi:10.3390/chemosensors6030041

Cited by 5 publications

(1 citation statement)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These intact cells represent a valuable opportunity to sample and assess the mutational landscape and immune profile of the metastases. It is important to note that the percentage of CTCs or CXCL13 + CD39 + tumor‐reactive T cells in peripheral blood is exceedingly low [80,81] . Accurate quantification of these cells might necessitate a dedicated cell capture system, which many clinics do not currently possess.…”

Section: Design Of Next‐generation Therapeuticsmentioning

confidence: 99%

Understanding the heterogeneous immune repertoire of brain metastases for designing next‐gen therapeutics

Wang,

Chen

2023

Brain-X

View full text Add to dashboard Cite

Approximately 20% of cancer patients experience brain metastases in the advanced stages as circulating tumor cells migrate to and colonize the brain microvasculature. Due to the challenges associated with biopsies, our understanding of the tumor microenvironment and heterogeneity in brain metastases remains limited, hindering the development of systemic approaches for detection and treatment. Emerging evidence suggests that specific brain metastases induce a substantial level of immune activation and infiltration, which provides an opportunity to design specific immunotherapies targeting brain metastases. This perspective aims to summarize recent advancements in molecular profiling of the immune repertoires of brain metastases using biopsy‐based approaches, with an emphasis on tumor‐reactive T cells. Additionally, we discuss the potential of alternative tissues and technologies that offer improved temporal resolution, throughput, and fidelity for tracking tumor dynamics.

show abstract

Section: Design Of Next‐generation Therapeuticsmentioning

confidence: 99%